Additionally, when we combined the treatment of blocking INSL5 or GPCR142 antibodies with conventional chemotherapy (DDP) in tumor‐bearing mice, we found that INSL5 overexpression displayed chemoresistance to DDP treatment, which can be reversed by INSL5 or GPCR142 antibody treatment (Fig EV5E–G). This evidence concerns the gene RXFP4 and neoplasm.